Testing of 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) in mouse L1210 leukemia and 37 sarcoma.

Abstract

The antimetabolite 2,3-dihydro-1,3-6H-oxazine-dione (3-oxauracil) has been investigated in an attempt to elucidate its effects on survival time of DBA/2 and B6D2F1 mice with L1210 leukemia and of outbred albino mice with 37 sarcoma. A significant increase in survival time was observed in mice with 37 sarcoma and slight effects were observed in mice with L1210 leukemia when treated with 3 x 12.5 or 3 x 25 mg/kg of 3-oxauracil. No toxic side effects were observed when large therapeutic doses of the drug were given.

• Authors: J N Stoychkov, J J Mircheva
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 62 Issue 12 Pg. 2121-3 (Dec 1978) ISSN: 0361-5960 [Print] United States
• PMID: 751720 (Publication Type: Journal Article)

Chemical References

• Oxazines
• 3-oxauracil
• Uracil

Topics

• Animals
• Drug Evaluation, Preclinical
• Female
• Leukemia L1210 (drug therapy)
• Male
• Mice
• Mice, Inbred Strains
• Oxazines (administration & dosage, pharmacology)
• Sarcoma, Experimental (drug therapy)
• Uracil (administration & dosage, analogs & derivatives, pharmacology)